Holen Sie sich die Stockscreener-App
2.97
0.00%
0.00
Handel nachbörslich:
2.97
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
PRME Q1 2026 Earnings: EPS Worse Than Expected as Pre-Revenue Biotech Advances PipelinePro Level Trade Signals - Newser
PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Consistency Score - Newser
Prime Medicine (PRME) Q1 2026 Disappoints — EPS $-0.28 Below $-0.26 ViewsEarnings Turnaround - Newser
Prime Medicine slips after Q4 updates - MSN
Prime Medicine (PRME) Reports Q1 EPS - Yahoo Finance
10 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $11 - Moomoo
TradingKey - TradingKey
Prime Medicine, Inc. (PRME) reports Q1 loss, misses revenue estimates - MSN
Number of shareholders of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
PRME Prime Medicine revenue jumps 55% YoY in Q1; shares rally 3% on growth momentum.Management Guidance - newser.com
JonesTrading Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $5 - Moomoo
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
The opportunity most miss about Prime Medicine (PRME) (-8.65%) 2026-05-08Analyst Recommended Stocks - Newser
Prime Medicine Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Prime Medicine (NASDAQ:PRME) Q1 Results Show Revenue Miss and Narrower Loss as Key Pipeline Milestones Loom - ChartMill
PRIME MEDICINE ($PRME) Releases Q1 2026 Earnings - Quiver Quantitative
[10-Q] Prime Medicine, Inc. Quarterly Earnings Report - Stock Titan
Prime Medicine Q1 net loss narrows as R&D expenses fall - TradingView
Prime Medicine (Nasdaq: PRME) Q1 2026 results, cash runway into 2027 and pipeline update - Stock Titan
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine targets 2 liver disease filings in 2026, data due 2027 - Stock Titan
Top Prime Medicine (PRME) Competitors 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen - MarketBeat
PRME SEC FilingsPrime Medicine 10-K, 10-Q, 8-K Forms - Stock Titan
PRME - Finviz
PRME Stock Price, Quote & Chart | PRIME MEDICINE INC (NASDAQ:PRME) - ChartMill
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Prime Medicine, Inc. ($PRME) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Prime Medicine, Inc. SEC Filing - Stock Titan
Prime Medicine (NASDAQ: PRME) details 2026 meeting, board elections and pay - Stock Titan
PRME (Prime Medicine Inc.) posts 55 percent year over year Q4 2025 revenue growth, shares rise modestly. - Xã Thanh Hà
Prime Medicine slides after pricing $125.4M stock offering - MSN
HC Wainwright & Co. Downgrades Prime Medicine (PRME) - MSN
Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer - Yahoo Finance
Bristol Myers Squibb (BMY) – Gene Editing Partner Prime Medicine (PRME) Announces Strategic CFO Hire, Bullish Analyst InitiationRisk Report - Cổng thông tin điện tử tỉnh Lào Cai
Prime Medicine (PRME) Financials 2026Income Statement and Balance Sheet - MarketBeat
Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (PRME) awards CFO 800,000 stock options at $3.67 - Stock Titan
Prime Medicine (PRME) CFO Makhni Svetlana Ni submits initial Form 3 - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):